Detalles de la búsqueda
1.
The McCAVE Trial: Vanucizumab plus mFOLFOX-6 Versus Bevacizumab plus mFOLFOX-6 in Patients with Previously Untreated Metastatic Colorectal Carcinoma (mCRC).
Oncologist
; 25(3): e451-e459, 2020 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-32162804
2.
Longitudinal analysis of organ-specific tumor lesion sizes in metastatic colorectal cancer patients receiving first line standard chemotherapy in combination with anti-angiogenic treatment.
J Pharmacokinet Pharmacodyn
; 47(6): 613-625, 2020 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-32865652
3.
Ang-2/VEGF bispecific antibody reprograms macrophages and resident microglia to anti-tumor phenotype and prolongs glioblastoma survival.
Proc Natl Acad Sci U S A
; 113(16): 4476-81, 2016 Apr 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-27044098
4.
Predictive potential of angiopoietin-2 in a mCRC subpopulation treated with vanucizumab in the McCAVE trial.
Front Oncol
; 13: 1157596, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37207143
5.
A first-in-human study of the fibroblast activation protein-targeted, 4-1BB agonist RO7122290 in patients with advanced solid tumors.
Sci Transl Med
; 15(695): eabp9229, 2023 05 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-37163618
6.
Vanucizumab mode of action: Serial biomarkers in plasma, tumor, and skin-wound-healing biopsies.
Transl Oncol
; 14(2): 100984, 2021 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-33338877
7.
Differential Effects of Ang-2/VEGF-A Inhibiting Antibodies in Combination with Radio- or Chemotherapy in Glioma.
Cancers (Basel)
; 11(3)2019 Mar 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-30845704
8.
First-in-Human Phase I Study of Single-agent Vanucizumab, A First-in-Class Bispecific Anti-Angiopoietin-2/Anti-VEGF-A Antibody, in Adult Patients with Advanced Solid Tumors.
Clin Cancer Res
; 24(7): 1536-1545, 2018 04 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29217526
9.
An apparent clinical pharmacokinetic drug-drug interaction between bevacizumab and the anti-placental growth factor monoclonal antibody RO5323441 via a target-trapping mechanism.
Cancer Chemother Pharmacol
; 79(4): 661-671, 2017 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-28314990
10.
A first-in-human phase I, multicenter, open-label, dose-escalation study of the oral RAF/VEGFR-2 inhibitor (RAF265) in locally advanced or metastatic melanoma independent from BRAF mutation status.
Cancer Med
; 6(8): 1904-1914, 2017 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-28719152
11.
Phase 1 dose-escalation study of the antiplacental growth factor monoclonal antibody RO5323441 combined with bevacizumab in patients with recurrent glioblastoma.
Neuro Oncol
; 17(7): 1007-15, 2015 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-25665807
Resultados
1 -
11
de 11
1
Próxima >
>>